Abstract:BACKGROUND Hepatocellular carcinoma (HCC) is the third leading cause of death from malignant tumors worldwide. More than 50% of HCC cases occur in China. The prognosis remains poor and overall efficacy is still unsatisfactory. Chemotherapy resistance is the most important reason for the poor outcome. Much progress has been made in the study of chemotherapy resistance of HCC; however, the specific mechanisms of progression of HCC have still only been partially established. Therefore, the mechanism of chemotherapy resistance in HCC requires more research. AIM To investigate the effect of miR-34a expression on the growth inhibition of HepG2 cells by doxorubicin. METHODS A recombinant lentiviral vector containing miR-34a was constructed and transfected into HepG2 cells. The expression of miR-34a was detected by reverse transcription-polymerase chain reaction (commonly known as RT-PCR) before and after transfection. Cells were exposed to 2 μM doxorubicin or phosphate-buffered saline before and after transfection. Cell viability in each group was detected by MTT assay, and cell cycle and apoptosis were detected by flow cytometry. Changes in expression levels of phospho (p)-p53, sirtuin (SIRT) 1, cyclin D1, cyclin-dependent kinase (CDK) 4, CDK6, BCL-2, multidrug resistance protein (MDR) 1/P glycoprotein (P-gp), and AXL were detected by Western blotting. RESULTS Recombinant lentiviral vector LV-hsa-mir-34a was successfully constructed by restriction endonuclease digestion and sequencing. RT-PCR showed that expression of miR-34a in HepG2 cells was significantly upregulated after transfection (P < 0.01). MTT assay showed that growth of HepG2 cells was inhibited after upregulation of miR-34a, and viability was significantly decreased after combined treatment with doxorubicin (P < 0.01). Flow cytometry showed that the number of HepG2 cells in G1 phase increased, and G1 phase arrest was more obvious after intervention with doxorubicin (P < 0.01). The apoptosis rate of HepG2 cells was increased after upregulation of miR-34a, and became more obvious after intervention with doxorubicin (P < 0.01). Western blotting showed that upregulation of miR-34a combined with treatment with doxorubicin caused significant changes in the expression levels of p-p53, SIRT1, cyclin D1, CDK4, CDK6, BCL-2, MDR1/P-gp and AXL proteins (P < 0.01). CONCLUSION MiR-34a may enhance the inhibitory effect of doxorubicin by downregulating MDR1/P-gp and AXL, which may be related to p53 expression.

Downregulation of histone deacetylase 1 by microRNA-520h contributes to the chemotherapeutic effect of doxorubicin.

Chemoresistance is Associated with Overexpression of HAX-1, Inhibition of Which Resensitizes Drug-Resistant Breast Cancer Cells to Chemotherapy.

Mir-520B Inhibits IGF-1R to Increase Doxorubicin Sensitivity and Promote Cell Apoptosis in Breast Cancer.

Hdac 1/4-Mediated Silencing of Microrna-200b Promotes Chemoresistance in Human Lung Adenocarcinoma Cells

Microrna-760 Inhibits Doxorubicin Resistance In Hepatocellular Carcinoma Through Regulating Notch1/Hes1-Pten/Akt Signaling Pathway

Study on microRNA-9-5p reducing sensitivity of breast cancer cells to doxorubicin through targeting HIC1

Microrna-522 Reverses Drug Resistance of Doxorubicin-Induced Ht29 Colon Cancer Cell by Targeting Abcb5

MiR-34a Overexpression Enhances the Inhibitory Effect of Doxorubicin on HepG2 Cells

Histone Deacetylase 2 Regulates Doxorubicin (dox) Sensitivity of Colorectal Cancer Cells by Targeting Abcb1 Transcription

Involvement of miR-30c in resistance to doxorubicin by regulating YWHAZ in breast cancer cells

Knockdown Of Heme Oxygenase-1 Promotes Apoptosis And Autophagy And Enhances The Cytotoxicity Of Doxorubicin In Breast Cancer Cells

HDAC6 Inhibition Protects Cardiomyocytes Against Doxorubicin-Induced Acute Damage by Improving Α-Tubulin Acetylation.

Histone deacetylase 1 induced by neddylation inhibition contributes to drug resistance in acute myelogenous leukemia

Doxorubicin resistance in breast cancer xenografts and cell lines can be counterweighted by microRNA-140-3p, through PD-L1 suppression

MicroRNA Expression Profiling Involved in Doxorubicin-Induced Cardiotoxicity Using High-Throughput Deep-Sequencing Analysis

Notch signaling pathway mediates Doxorubicin-driven apoptosis in cancers.

Silencing HDAC1 Expression Regulates Extracellular Regulated Protein Kinases/Mitogen-Activated Protein Kinase Signaling Activation and Enhances Chemosensitivity of Ovarian Carcinoma

miRNA-200c increases the sensitivity of breast cancer cells to doxorubicin through the suppression of E-cadherin-mediated PTEN/Akt signaling.

Protective Effect of Long Noncoding RNA OXCT1-AS1 on Doxorubicin-Induced Apoptosis of Human Myocardial Cells by the Competitive Endogenous RNA Pattern

Long non-coding RNA SNHG1 protects human AC16 cardiomyocytes from doxorubicin toxicity by regulating miR-195/Bcl-2 axis

Histone deacetylases 1 and 2 cooperate in regulating BRCA1, CHK1, and RAD51 expression in acute myeloid leukemia cells.